# RPL10

Source: https://onco.cc/targets/rpl10/  
OnCo record `rpl10` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RPL10 (Large ribosomal subunit protein uL16) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 1 more.

## Summary

Component of the large ribosomal subunit. Plays a role in the formation of actively translating ribosomes. May play a role in the embryonic brain development.

Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.81, genetic association 0.00, somatic mutation 0.83, clinical 0.11). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Non-Hodgkin Lymphoma, Plasma Cell Myeloma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: ribosomal protein L10; Large ribosomal subunit protein uL16; DXS648E; DXS648; FLJ23544; L10; uL16
- Tags: cancer-genes-wave
- Symbol: RPL10
- Class: oncogene
- Biology: Component of the large ribosomal subunit. Plays a role in the formation of actively translating ribosomes. May play a role in the embryonic brain development. Location: Cytoplasm (UniProt). Locus Xq28 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.58 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 1 cohort (NHL); Multiple myeloma: IntOGen driver in 1 cohort (PCM); Leukaemia: Open Targets association 0.52 with leukaemia (MONDO_0005059); Acute lymphoblastic leukaemia: Open Targets association 0.50 with acute lymphoblastic leukaemia (MONDO_0004967)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.19; IntOGen calls it an activating (Act) driver in 2 cohorts. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:10298: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10298
- UniProt P27635: https://www.uniprot.org/uniprotkb/P27635/entry
- NCBI Gene 6134: https://www.ncbi.nlm.nih.gov/gene/6134
- Ensembl ENSG00000147403: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147403

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/rpl10.json